Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.
Hermes Biosciences has raised $6.0M in total funding. The most recent round was Seed. The last funding was announced in November 2025.
Hermes Biosciences's investors include Paladin Capital Group, Vertical Venture Partners, Genoa Ventures.
Hermes Biosciences is headquartered in San Francisco, United States.
Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.
Hermes Biosciences is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hermes Biosciences — Funding & Investors." VCBacked, November 18, 2025, https://www.vcbacked.co/company/hermes-biosciences. Accessed August 1, 2026.
VCBacked. (2025). Hermes Biosciences — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/hermes-biosciences
{{cite web |title=Hermes Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/hermes-biosciences |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated